,i #aaith ,,congress #b;d ,session ,h4 ,r4 #gjej ,,in ,,the ,,house ,,of ,,representatives ,january #ad1 #bjbf,mr4 ,sessions 7for himself1 ,mr4 ,kennedy of ,utah1 and ,mr4 ,jackson of ,illinois7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act with respect to homeopathic drug products1 and for other purposes4 #a4 ,short title2 table of contents 7a7 ,short title ,this ,act may be cited as the ,homeopathic ,drug ,product ,safety1 ,quality1 and ,transparency ,act4 7b7 ,table of contents ,the table of contents for this ,act is as follows3 ,sec4 #a4 ,short title2 table of contents4,sec4 #b4 ,purpose2 sense of ,congress4,sec4 #c4 ,definitions4,sec4 #d4 ,safety1 quality1 and transparency requirements for homeopathic drug products4,sec4 #e4 ,conforming amendments4,sec4 #f4 ,withdrawal of guidance4,sec4 #g4 ,severability4 #b4 ,purpose2 sense of ,congress 7a7 ,purpose ,the purpose of this ,act is to address consumer and practitioner needs for continued access to homeopathic drug products that meet requirements for safety1 quality1 and transparency4 7b7 ,sense of ,congress ,it is the sense of ,congress that-- 7#a7 homeopathic medicines are important to millions of ,american consumers1 and continued consumer access to safe homeopathic products is best ensured by enacting a distinct statutory pathway for the regulation of homeopathic drug products2 and 7#b7 while the ,federal ,government should continue to take appropriate action against products that are adulterated or misbranded1 ,federal agencies should not impose regulatory barriers that unreasonably limit or prevent consumer and health care provider access to safe products and accurate information4 #c4 ,definitions ,section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7 is amended-- 7#a7 in paragraph 7p71 by striking except a new animal drug or an animal feed bearing or containing a new animal drug each place it appears and inserting except a new animal drug1 an animal feed bearing or containing a new animal drug1 or a homeopathic drug product2 7#b7 in paragraph 7v71 by inserting before the period at the end the following3 1 and that a homeopathic drug product is not a new animal drug2 and 7#c7 by adding at the end the following3 7tt7 ,the term homeopathic drug product means a drug that-- 7#a7 contains #a or more homeopathic ingredients2 and 7#b7 contains no other active ingredient4 7uu7 ,the term homeopathic ingredient means an ingredient-- 7#a7 listed in the ,homeopathic ,pharmacopoeia of the ,united ,states or a ,state homeopathic formulary2 or 7#b7 prepared pursuant to homeopathic safety and quality standards described in-- 7,a7 the ,homeopathic ,pharmacopoeia of the ,united ,states or any other officially recognized homeopathic pharmacopoeia2 or 7,b7 any accredited voluntary consensus standard for homeopathic drug products1 as determined by the ,secretary in compliance with section #ab7;d7 of the ,national ,technology ,transfer and ,advancement ,act of #aiie4 4 #d4 ,safety1 quality1 and transparency requirements for homeopathic drug products ,subchapter ,a of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cea et seq47 is amended by inserting after section #ejc;,d 7#ba ,u4,s4,c4 #cec;d7 the following3 #ejc;,e4 ,homeopathic drug products 7a7 ,provisions applicable to homeopathic drug products 7#a7 ,chapter ,v provisions ,no section of this chapter shall apply to homeopathic drug products except this section and sections #eja1 #ejb1 and #eaj4 7#b7 ,requirements for all provisions ,no provision of law1 a regulation1 or a guidance document 7including sections #eja1 #ejb1 and #eaj and any applicable provisions of this ,act outside of this chapter7 shall apply to homeopathic drug products unless such provision-- 7,a7 does not conflict with this section2 and 7,b7 does not impose standards that are in conflict with standards in the ,homeopathic ,pharmacopoeia of the ,united ,states or in an accredited voluntary consensus standard for homeopathic drug products1 as determined by the ,secretary in compliance with section #ab7;d7 of the ,national ,technology ,transfer and ,advancement ,act of #aiie4 7b7 ,adulteration2 good manufacturing practice standards 7#a7 ,adulteration ,a homeopathic drug product shall be deemed to be adulterated if it does not comply with-- 7,a7 the safety and quality standards and manufacturing practices described in-- 7i7 the ,homeopathic ,pharmacopoeia of the ,united ,states or any other officially recognized homeopathic pharmacopoeia2 or 7ii7 an accredited voluntary consensus standard for homeopathic drug products1 as determined by the ,secretary in compliance with section #ab7;d7 of the ,national ,technology ,transfer and ,advancement ,act of #aiie2 or 7,b7 in the case that no standard or manufacturing practice described in subparagraph 7,a7 applies to such homeopathic drug product1 the regulations described in paragraph 7#b74 7#b7 ,alternative regulations ,the regulations described in this paragraph are the following3 7,a7 ,good manufacturing practice regulations promulgated under section #eja7;a77#b7 or related guidance documents1 provided that such regulations or related guidance documents do not conflict with any other provision of this section4 7,b7 ,in the case that no regulation described in subparagraph 7,a7 applies to the homeopathic drug product1 a new good manufacturing practice regulation1 which shall be promulgated by the ,secretary after notice and opportunity for public comment pursuant to chapter #e of title #e1 ,united ,states ,code-- 7i7 that does not conflict with any other provision of this section2 7ii7 that is specific to and appropriate for homeopathic drug products2 and 7iii7 with respect to which the ,secretary has requested and received a favorable recommendation from the ,homeopathic ,drug ,product ,advisory ,committee4 7#c7 ,petition for exemption1 variance1 or alternative standard or practice 7,a7 ,petition ,a manufacturer of a homeopathic drug product subject to a good manufacturing practice regulation may submit to the ,secretary a petition for an exemption1 variance1 or alternative standard or practice with respect to such product4 ,the ,secretary shall refer such petition to the ,homeopathic ,drug ,product ,advisory ,committee1 which shall report its recommendation to the ,secretary not later than #fj days after receiving such petition4 7,b7 ,deadline for approval ,the ,secretary shall make a decision on a petition submitted under subparagraph 7,a7 not later than #ahj days after the submission of the petition4 ,if the ,secretary fails to make a decision on such a petition within such #ahj-;day period1 the petition shall be deemed approved and the proposed exemption1 variance1 or alternative standard or practice established4 7,c7 ,standard for approval ,the ,secretary may approve a petition submitted under subparagraph 7,a7 and establish the proposed exemption1 variance1 or alternative standard or practice with respect to the homeopathic drug product only if such exemption1 variance1 or alternative standard or practice does not affect the safety of the homeopathic drug product4 7,d7 ,judicial review ,for the purposes of chapter #g of title #e1 ,united ,states ,code1 a decision of the ,secretary on a petition submitted under subparagraph 7,a7 shall be considered final agency action4 7#d7 ,final and intermediate product testing 7,a7 ,final product testing ,a finished homeopathic drug product shall be exempt from the requirement for a laboratory determination of identity and strength of each active ingredient described in section #baa4afe7;a7 of title #ba1 ,code of ,federal ,regulations 7or any successor regulation71 but shall continue to be required to meet other final specifications1 such as testing for contaminants and defects of the finished product1 consistent with this section4 7,b7 ,intermediate testing for certain starting materials 7i7 ,in general ,the manufacturer of a homeopathic drug product made from a starting material containing a substance which may present a substantial risk of illness or injury in its undiluted form shall ensure and document that the amount of such substance in an intermediate level preparation used to make all further attenuations does not exceed a safe level1 as determined by the ,secretary under this subparagraph4 7ii7 ,safe level defined ,in this subparagraph1 the term safe level means-- 7,i7 a level set by nationally recognized standards for safety1 including the ,homeopathic ,pharmacopoeia of the ,united ,states or an accredited voluntary consensus standard for homeopathic drug products1 as determined by the ,secretary in compliance with section #ab7;d7 of the ,national ,technology ,transfer and ,advancement ,act of #aiie2 or 7,,ii7 in the absence of a standard described in subclause 7,i71 a level below an analytically detectable presence4 7iii7 ,publication of safe levels ,the ,secretary may issue an order1 notice of which shall be published in the ,federal ,register1 establishing a safe level1 based on appropriate scientific and technical data1 for a substance under clause 7i74 ,such notice shall include-- 7,i7 a statement of the basis for the ,secretary's finding that there is a reasonable probability that the substance may present a substantial risk of illness or injury in its undiluted form2 7,,ii7 a statement of the basis for the establishment of the safe level1 including any available methods to establish such level2 and 7,,iii7 a request for public comments4 7c7 ,misbranding 7#a7 ,in general ,a drug shall be deemed to be misbranded if-- 7,a7 it is not a homeopathic drug product1 and its labeling bears the term homeopathic1 homeopathy1 homeopath1 or such similar term as determined by the ,secretary2 or 7,b7 it is a homeopathic drug product1 and its labeling does not comply with the requirements described in paragraph 7#b74 7#b7 ,labeling requirements ,with respect to the labeling of a homeopathic drug product1 the requirements described in this paragraph are the requirements for the labeling of a drug under this ,act1 subject to the following3 7,a7 ,the labeling need not adhere to any requirement that does not apply to homeopathic drug products under subsection 7a74 7,b7 ,the dosage units of the homeopathic ingredients shall be expressed as attenuations particular to homeopathic ingredients 7such as #cx or #f;c74 7,c7 ,if the homeopathic drug product is not intended for retail sale1 the label of such product need not contain a purpose or indication for use4 7,d7 ,if the homeopathic drug product is intended for retail sale1 the label of such product shall contain-- 7i7 #a or more purposes or indications for use for self-limiting conditions that are supported by-- 7,i7 the ,homeopathic ,pharmacopoeia of the ,united ,states1 an official pharmacopeia of another country where the practice of homeopathy is licensed or certified1 or an accredited voluntary consensus standard for homeopathic drug products1 as determined by the ,secretary in compliance with section #ab7;d7 of the ,national ,technology ,transfer and ,advancement ,act of #aiie2 7,,ii7 a traditional homeopathic reference1 including a homeopathic ,materia ,medica in general use by licensed medical practitioners who practice homeopathy or certified homeopaths in the ,united ,states or another country2 7,,iii7 a peer-reviewed medical journal1 including any homeopathic medical journal2 7,,iv7 citation to scientific evidence1 including clinical data or trials2 7,v7 beneficial clinical usage documented by clinical reports from national or international organizations1 professionally recognized publications of clinical indications and contraindications1 national or international instructional courses providing training in the use of homeopathic drug products1 or professional peer review presentations of physicians' usage results with homeopathic drug products at local1 county1 ,state1 national1 or international meetings2 or 7,,vi7 quality real-world data that provides sufficient evidence to support such purposes or indications for use2 and 7ii7 adjacent to such purposes or indications for use1 the following statement3 ,these indications have not been evaluated by the ,food and ,drug ,administration4 ,this product is intended for traditional homeopathic uses44 7,e7 ,the labeling shall not be considered false or misleading for the purposes of section #ejb7;a77#a7 due to the inclusion of a purpose or indication for use that is supported by any source described in subclauses 7,i7 through 7,,vi7 of subparagraph 7,d77i74 7,f7 7i7 ,subject to clause 7ii71 the label shall describe-- 7,i7 the source relied upon for each purpose or indication for use under subparagraph 7,d77i72 and 7,,ii7 if applicable1 the name and place of business of any parent1 subsidiary1 or affiliate company of the manufacturer of the homeopathic drug product1 if under common ownership or control4 7ii7 ,if the label has insufficient space for the information required by clause 7i71 in lieu of such information the label may contain a quick response code 7commonly known as a ,,qr code7 or similar mechanism that links to a publicly accessible website containing such information4 7#c7 ,application of other misbranding-related provisions 7,a7 ,,ftc ,act ,labeling or marketing claims associated with a homeopathic drug product that are in compliance with this subsection may not be considered a false advertisement or an unfair or deceptive act or practice in or affecting commerce for purposes of section #e or #ab of the ,federal ,trade ,commission ,act4 7,b7 ,other provisions of ,federal or ,state law ,if a homeopathic drug product's label1 labeling1 advertising1 and marketing materials are in compliance with this subsection1 no other substantiation requirement in ,federal or ,state law shall apply to such product4 7,c7 ,private rights of action ,no private right of action for false or deceptive advertising may be predicated on the lack of clinical trials to substantiate indications for a homeopathic drug product4 7d7 ,registration and listing ,for purposes of drug establishment registration and drug listing under section #eaj1 the ,secretary shall-- 7#a7 designate a homeopathic drug product establishment as a homeopathic establishment2 and 7#b7 list a homeopathic drug product as homeopathic1 with no other designation4 7e7 ,no premarket approval ,the ,secretary may not require premarket approval of a homeopathic drug product4 7f7 ,homeopathic ,drug ,product ,advisory ,committee 7#a7 ,establishment ,the ,secretary shall establish a ,homeopathic ,drug ,product ,advisory ,committee 7in this subsection referred to as the ,committee7 to advise the ,secretary on the regulation of homeopathic drug products4 7#b7 ,membership 7,a7 ,in general ,subject to subparagraph 7,b71 the ,committee shall be composed of #aj members1 to be appointed by the ,secretary1 as follows3 7i7 #a representative from an organization of homeopathic product consumers that has been operating for a minimum of #c continuous years with a minimum of #aj1jjj members1 who shall serve as the ,chair of the ,committee4 7ii7 #a representative from a domestic homeopathic drug manufacturer that produces at least #ej distinct homeopathic drug products and has no fewer than #ej employees4 7iii7 #a representative from a domestic homeopathic drug manufacturer that produces at least #ej distinct homeopathic drug products and has no more than #ej employees4 7iv7 #a representative from the ,homeopathic ,pharmacopoeia ,convention of the ,united ,states4 7v7 #a representative from an accredited voluntary consensus standards body for homeopathic drug products that has been operating for a minimum of #c continuous years4 7vi7 #a licensed medical doctor 7,m4,d47 or doctor of osteopathy 7,d4,o47 who holds a ,diplomate1 ,american ,board of ,homeopathic ,medicine 7,,dabhm7 or ,diplomate1 ,homeotherapeutics 7,d,ht7 and who maintains a homeopathic practice that has been in operation for a minimum of #c continuous years4 7vii7 #a licensed naturopathic doctor 7,n4,d47 who holds a ,diplomate1 ,american ,board of ,homeopathic ,medicine 7,,dabhm7 or ,diplomate1 ,homeopathic ,academy of ,naturopathic ,physicians 7,,dhanp7 and who maintains a homeopathic practice that has been in operation for a minimum of #c continuous years4 7viii7 #a licensed pharmacist or chemist actively engaged in the preparation of homeopathic drug products for a minimum of #c continuous years4 7ix7 #a licensed veterinarian certified by the ,academy of ,veterinary ,homeopathy or accredited by a recognized homeopathy institution who maintains a practice that has been in operation for a minimum of #c continuous years4 7x7 ,the ,commissioner of ,food and ,drugs4 7,b7 ,alternative members ,if the ,secretary is unable to find a suitable individual to serve in the position of a representative described in clauses 7i7 through 7ix71 the other members of the ,committee may appoint to such position1 by majority vote1 such other expert in the field of homeopathic drug products as the ,committee determines appropriate4 7,c7 ,balance of membership ,in making appointments under subparagraph 7,a71 the ,secretary shall ensure that the membership of the ,committee reflects a proper balance of perspectives from the homeopathic practitioner1 manufacturer1 and consumer communities4 7,d7 ,no compensation ,the members of the ,committee shall serve without compensation4 7#c7 ,frequency of sessions ,the ,secretary shall call the ,committee into session at such times and in such places as the ,secretary determines appropriate1 but in no case less frequently than once every #c months4 7#d7 ,investigations ,the ,committee may investigate any report of a homeopathic drug product to the ,,fda ,adverse ,event ,reporting ,system to assist in post-market surveillance4 7#e7 ,termination ,section #ajac of chapter #e1 ,united ,states ,code 7relating to termination of advisory committees71 shall not apply to the ,committee4 7g7 ,inspectors ,all ,federal inspectors whose duties or authorities extend to homeopathic drug products shall be familiar with the requirements of this section1 including the safety and quality manufacturing standards in the ,homeopathic ,pharmacopoeia of the ,united ,states or an accredited voluntary consensus standard for homeopathic drug products4 7h7 ,non-,preemption of ,state law on practice of homeopathy ,nothing in this section shall be construed to preempt1 limit1 or interfere with ,state jurisdiction concerning the practice of homeopathy and related activities within the scope of the health care professional-patient relationship4 7i7 ,burden of proof ,the ,united ,states shall bear the burden of proof to establish a violation of this section4 ,any ,federal court with jurisdiction shall decide any matter under this section on a de novo basis4 4 #e4 ,conforming amendments 7a7 ,pharmaceutical ,distribution ,supply ,chain ,section #eha7ac7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;eee7#ac77 is amended by striking homeopathic drugs marketed in accordance with applicable guidance under this ,act and inserting homeopathic drug products marketed in accordance with this ,act4 7b7 ,serious adverse event reporting for nonprescription drugs ,section #gfj7;a77#b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;aa7a77#b77 is amended to read as follows3 7#b7 ,nonprescription drug ,the term nonprescription drug-- 7,a7 means a drug that is-- 7i7 not subject to section #ejc7;b72 and 7ii7 not subject to approval in an application submitted under section #eje2 and 7,b7 includes a homeopathic drug product4 4 7c7 ,exemption from regulation of biological products ,section #cea7;i77#a7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;i77#a77 is amended by adding at the end the following3 ,such term does not include a homeopathic drug product 7as defined in section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act744 #f4 ,withdrawal of guidance ,the guidance of the ,food and ,drug ,administration titled ,homeopathic ,drug ,products2 ,guidance for ,food and ,drug ,administration ,staff and ,industry2 ,availability 7#hg ,fed4 ,reg4 #gejed2 published on ,december #g1 #bjbb7 shall have no force or effect with respect to homeopathic drug products 7as defined in section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba71 as amended by section #c7c774 #g4 ,severability ,if any provision of this ,act 7including the amendments made by this ,act7 is declared unconstitutional1 or the applicability of this ,act 7including the amendments made by this ,act7 to any person or circumstance is held invalid1 the constitutionality of the remainder of this ,act 7including the amendments made by this ,act7 and the applicability thereof to other persons and circumstances shall not be affected4